Clinical use of erythropoietin in chronic kidney disease: Outcomes and future prospects

Hippokratia

Volumn 15, Issue 2, 2011, Pages 109-115

  Provatopoulou, Simella T ^a   Ziroyiannis, P N ^b  

^a IASO GENERAL HOSPITAL   (Greece)

^b Department of Medicine   (Greece)

Author keywords

Anemia correction; Cardiovascular; Erythropoietin; Extra hematopoietic actions; Hyporesponsiveness; Renoprotection; Review

Indexed keywords

ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; INTERLEUKIN 10; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BRAIN INJURY; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CHRONIC KIDNEY DISEASE; COGNITION; COMORBIDITY; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; DIABETIC NEUROPATHY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; ERYTHROPOIESIS; EXERCISE TOLERANCE; FETUS DEVELOPMENT; FUNCTIONAL STATUS; HEART MUSCLE ISCHEMIA; HEMATOPOIESIS; HEMODIALYSIS; HUMAN; HYPERTENSION; INHIBITION KINETICS; MORBIDITY; MORTALITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEAL DIALYSIS; PLEIOTROPY; POLYNEUROPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SINGLE DRUG DOSE; SPINAL CORD INJURY; SUBARACHNOID HEMORRHAGE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 79955418744     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590.
2. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.
3. Dróeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084.
4. Singh AK. The controversy surrounding hemoglobin and erythropoiesis stimulating agents: What should we do now? Am J Kidney Dis. 2008; 52: S5-S13.
5. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005; 16: 2180-2189.
6. Reddan D, Lappin DW, Tierney M, Szczech LA. What have we learned about PD from recent major clinical trials? Perit Dial Int. 2007; 27: 395-399.
7. National Kidney Foundation: KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 Update of hemoglobin target. Am J Kidney Dis. 2007; 50: 471-530.
8. US Food and Drug Administration and Center for Drug Evaluation and Research: Information for healthcare professionals: Erythropoiesis Stimulating Agents (ESA). [Accessed: 2008 February 25]. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm.
9. Singh AK. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD Anemia: Pro. J Am Soc Nephrol. 2009; 20: 1436-1443.
10. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369: 381-388.
11. Rosner MH, Bolton WK. The mortality risk associated with higher hemoglobin: is the therapy to blame? Kidney Int. 2008; 74: 695-697.
12. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008; 74: 791-798.
13. Vaziri ND. Anemia and anemia correction: Surrogate markers or causes of morbidity in chronic kidney disease? Nat Rev Nephrol. 2008; 4: 436-445.
14. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17: 1181-1191.
15. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004; 44: 866-876.
16. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009; 4: 470-480.
17. Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant. 2009; 24: 1082-1088.
18. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, et al: DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18: 975-984.
19. st ed. San Diego, CA: Elsevier Academic Press. 2009, p. 27-33.
20. Arcasoy MO. The non-hematopoietic biological effects of erythropoietin. Brit J Haematol. 2008; 141: 14-31.
21. Bahlmann FH, Kielstein JT, Haller H, Fliser D. Erythropoietin and progression of CKD. Kidney Int. 2007; 72: S21-S25.
22. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens. 2009; 18: 15-20.
23. d'Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension. 2007; 49: 1142-1148.
24. Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem. 2007; 282: 25875-25883.
25. Nakano M, Satoh K, Fukumoto Y, Ito Y, Kagaya Y, Ishii Naoto, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 2007; 100: 662-669.
26. Andreotti F, Agati L, Conti E, Santucci E, Rio T, Tarantino F, et al. Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythropoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). J Thromb Thrombolysis. 2009; 28: 489-495.
27. Breggia AC, Wojchowski DM, Himmelfarb J. JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells. Am J Physiol Renal Physiol. 2008; 295: F1689-F1695.
28. Bi B, Guo J, Marlier A, Lin SR, Cantley LG. Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol. 2008; 295: F1017-F1022.
29. Kitamura H, Isaka Y, Takabatake Y, Imamura R, Suzuki C, Takahara S, et al. Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant. 2008; 23: 1521-1528.
30. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial akt and attenuates progressive organ failure. Circulation. 2004; 110: 1006-1012.
31. Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int. 2007; 72: 455-463.
32. Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int. 2007; 72: 489-49.